Chinook Therapeutics Inc. (KDNY)
40.39
0.09 (0.22%)
At close: Aug 10, 2023, 8:00 PM
0.22% (1D)
| Bid | n/a |
| Market Cap | 2.71B |
| Revenue (ttm) | 5.85M |
| Net Income (ttm) | -243.21M |
| EPS (ttm) | -3.24 |
| PE Ratio (ttm) | -12.466049382716049 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 3,281,100 |
| Avg. Volume (20D) | 2,044,466 |
| Open | 40.31 |
| Previous Close | 40.30 |
| Day's Range | 40.30 - 40.51 |
| 52-Week Range | 18.34 - 40.51 |
| Beta | 0.67 |
About KDNY
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. Its product candidates also include BION-1301, an anti-APRIL monoclonal antibody is being evaluated in ...
Industry Biotechnology
Sector Healthcare
IPO Date Oct 6, 2020
Employees 214
Stock Exchange NASDAQ
Ticker Symbol KDNY
Website https://www.chinooktx.com